Published in Antimicrob Agents Chemother on June 01, 1984
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (1985) 2.48
Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob Agents Chemother (1985) 2.36
Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum. Antimicrob Agents Chemother (1986) 1.57
In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1988) 1.53
In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents. Antimicrob Agents Chemother (1985) 1.49
Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories. J Clin Microbiol (1984) 1.30
In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin. Antimicrob Agents Chemother (1991) 1.28
Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother (1994) 1.23
Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother (1992) 1.17
TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1995) 1.10
Antimicrobial activity of HR810 against 419 strict anaerobic bacteria. Antimicrob Agents Chemother (1985) 1.03
Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (1991) 1.00
The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years. Infection (1994) 0.98
Interaction of cefpirome and a cephalosporinase from Citrobacter freundii GN7391. Antimicrob Agents Chemother (1989) 0.94
MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin. J Clin Microbiol (1992) 0.94
In vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria. Antimicrob Agents Chemother (1993) 0.88
Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin. J Clin Microbiol (1986) 0.85
In vitro antibacterial effects of cephalosporins. Drugs (1987) 0.84
In vitro activity of DQ-2556, a new cephalosporin. Antimicrob Agents Chemother (1986) 0.84
Microanalytical high-performance liquid chromatography assay for cefpirome (HR 810) in serum. Antimicrob Agents Chemother (1988) 0.81
Distribution of cefpirome (HR 810) to exudate in the croton oil-induced rat granuloma pouch and its therapeutic effects on experimental infections in the pouch. Antimicrob Agents Chemother (1988) 0.80
In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents Chemother (1992) 0.78
Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus. Antimicrob Agents Chemother (1985) 0.76
Preliminary interpretive susceptibility testing criteria for FK-037 with 30-microgram disks. J Clin Microbiol (1994) 0.75
In vitro and in vivo activities of DQ-2556 and its mode of action. Antimicrob Agents Chemother (1992) 0.75
Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother (1972) 61.10
The beta-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol (1973) 25.78
The new beta-lactamase-stable cephalosporins. Ann Intern Med (1982) 7.20
In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains. Antimicrob Agents Chemother (1980) 5.37
Indirect method for assessing the penetration of beta-lactamase-nonsusceptible penicillins and cephalosporins in Escherichia coli strains. Antimicrob Agents Chemother (1976) 5.18
Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med (1983) 3.97
In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases. Antimicrob Agents Chemother (1980) 3.68
Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother (1980) 3.14
Monobactams--monocyclic beta-lactam antibiotics produced by bacteria. J Antimicrob Chemother (1981) 2.68
The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime. J Antibiot (Tokyo) (1979) 2.67
Treatment of infections due to methicillin-resistant Staphylococcus aureus. Ann Intern Med (1982) 2.57
In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin. Antimicrob Agents Chemother (1981) 2.45
Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity. Rev Infect Dis (1983) 2.00
HR 810, a cephalosporin with low affinity for Enterobacter cloacae beta-lactamase. Eur J Clin Microbiol (1983) 1.59
Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria. Antimicrob Agents Chemother (1981) 1.55
Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics. Rev Infect Dis (1983) 1.43
Relation between beta-lactamase production and antimicrobial activity: comparison of the new compound HR 810 with cefotaxime. Eur J Clin Microbiol (1983) 1.38
Antimicrobial activity, beta-lactamase stability and beta-lactamase inhibition of cefotetan and other 7-alpha-methoxy beta-lactam antimicrobials. Diagn Microbiol Infect Dis (1983) 1.37
In vitro activity of HR 810, a new broad-spectrum cephalosporin. Eur J Clin Microbiol (1983) 1.30
Susceptibility of gram-positive aerobic cocci to the new cephalosporin HR 810. Eur J Clin Microbiol (1983) 1.18
Clinical use of the new beta-lactam antimicrobial drugs. Practical considerations for physicians, microbiology laboratories, pharmacists, and formulary committees. Ann Intern Med (1983) 1.08
Laboratory evaluation of a rapid, automatic susceptibility testing system: report of a collaborative study. Antimicrob Agents Chemother (1975) 17.12
Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis (1999) 10.30
Successful use of broth microdilution in susceptibility tests for methicillin-resistant (heteroresistant) staphylococci. J Clin Microbiol (1983) 9.99
An improved single-disk method for testing the antibiotic susceptibility of rapidly-growing pathogens. Am J Clin Pathol (1970) 8.90
Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study. J Clin Microbiol (1981) 8.49
Evaluation of the micro-media system for quantitative antimicrobial drug susceptibility testing: a collaborative study. Antimicrob Agents Chemother (1978) 8.08
Ampicillin resistance in Haemophilus influenzae as determined by a rapid test for beta-lactamase production. Antimicrob Agents Chemother (1974) 7.57
Halophilic Vibrio species isolated from blood cultures. J Clin Microbiol (1976) 7.48
The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit. Ann Intern Med (1982) 6.62
Antimicrobial susceptibility of Haemophilus influenzae. Antimicrob Agents Chemother (1974) 6.61
The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins. J Clin Microbiol (1986) 6.00
Clinical laboratory evaluation of the Abbott MS-2 automated antimicrobial susceptibility testing system: report of a collaborative study. J Clin Microbiol (1980) 5.99
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother (1995) 5.74
In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains. Antimicrob Agents Chemother (1980) 5.37
Evaluation of the Sensititre system for quantitative antimicrobial drug susceptibility testing: a collaborative study. Antimicrob Agents Chemother (1980) 5.34
Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1994) 5.33
Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1979) 5.10
Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol (1991) 4.79
In-vitro methods for determining minimal lethal concentrations of antimicrobial agents. Am J Clin Pathol (1979) 4.66
Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity? Clin Infect Dis (2007) 4.51
Rapid determination of antimicrobial susceptibility for urgent clinical situations. Am J Clin Pathol (1973) 4.18
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother (1984) 4.13
Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother (1985) 4.09
Probabilities will help us plan for climate change. Nature (2001) 4.04
Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother (2000) 4.03
Reliability of the microdilution technic for detection of methicillin-resistant strains of staphylococcus aureus. Am J Clin Pathol (1977) 4.02
Spectinomycin-resistant penicillinase-producing Neisseria gonorrhoeae. Lancet (1981) 4.02
Problems with the disk diffusion test for detection of vancomycin resistance in enterococci. J Clin Microbiol (1989) 3.97
Effect of temperature on the in vitro susceptibility of Staphylococcus aureus to penicillinase-resistant penicillins. Antimicrob Agents Chemother (1973) 3.89
Evaluation of the Sceptor microdilution antibiotic susceptibility testing system: a collaborative investigation. J Clin Microbiol (1981) 3.86
Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob Agents Chemother (1982) 3.82
Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole. J Clin Microbiol (1994) 3.77
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis (1998) 3.76
New recommendations for disk diffusion antimicrobial susceptibility tests for methicillin-resistant (heteroresistant) staphylococci. J Clin Microbiol (1984) 3.76
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother (2002) 3.74
Statistical criteria for selecting quality control limits for broth microdilution susceptibility tests with 39 different antimicrobial agents. Collaborative Antimicrobial Susceptibility Testing Group. Diagn Microbiol Infect Dis (1990) 3.71
In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs. Antimicrob Agents Chemother (1983) 3.70
Identification of Staphylococcus aureus by simultaneous use of tube coagulase and thermonuclease tests. Appl Microbiol (1973) 3.70
National gonorrhea therapy monitoring study: in vitro antibiotic susceptibility and its correlation with treatment results. N Engl J Med (1976) 3.63
National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis (1998) 3.58
Reliability of the Kirby-Bauer disc diffusion method for detecting methicillin-resistant strains of Staphylococcus aureus. Appl Microbiol (1972) 3.55
Evaluation of the sensititre microdilution antibiotic susceptibility system against recent clinical isolates: three-laboratory collaborative study. J Clin Microbiol (1980) 3.49
Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol (2001) 3.49
Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother (1987) 3.47
Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother (1998) 3.45
National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother (1988) 3.40
In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother (2002) 3.36
Effect of calcium and magnesium ions on the susceptibility of Pseudomonas species to tetracycline, gentamicin polymyxin B, and carbenicillin. Antimicrob Agents Chemother (1975) 3.32
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother (1997) 3.17
Rapid identification of Enterobacteriaceae with the micro-ID system versus API 20E and conventional media. J Clin Microbiol (1979) 3.17
Short-term storage of six penicillins and cephalothin in microdilution trays for antimicrobial susceptibility tests. Antimicrob Agents Chemother (1976) 3.12
In vitro activity of antimicrobial agents on Legionnaires disease bacterium. Antimicrob Agents Chemother (1978) 3.11
International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis (1999) 3.11
Effect of culture medium and carbon dioxide concentration on growth of anaerobic bacteria commonly encountered in clinical specimens. Appl Microbiol (1974) 3.10
Evidence for two distinct types of penicillinase-producing Neisseria gonorrhoeae. Lancet (1977) 3.09
Antibiotic susceptibility of Streptococcus bovis and other group D streptococci causing endocarditis. Antimicrob Agents Chemother (1974) 3.06
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother (1998) 3.06
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrob Agents Chemother (1984) 3.04
Broth-dilution method for determining the antibiotic susceptibility of anaerobic bacteria. Antimicrob Agents Chemother (1975) 2.96
Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline. J Clin Microbiol (1989) 2.96
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis (1998) 2.96
National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis (1998) 2.94
Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol (2002) 2.94
Screening pneumococci for penicillin resistance. J Clin Microbiol (1986) 2.94
Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin. Antimicrob Agents Chemother (1980) 2.92
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother (2003) 2.92
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol (2003) 2.89
Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis (2001) 2.86
In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother (2001) 2.84
Molecular analysis of Tn1546 in Enterococcus faecium isolated from animals and humans. J Clin Microbiol (1998) 2.81
Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unit. Diagn Microbiol Infect Dis (1993) 2.81
Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagn Microbiol Infect Dis (1986) 2.77
Inoculum standardization in antimicrobial susceptibility testing: evaluation of overnight agar cultures and the Rapid Inoculum Standardization System. J Clin Microbiol (1983) 2.71
Disc agar diffusion antimicrobial susceptibility tests with beta-lactamase producing Neisseria gonorrhoeae. J Antibiot (Tokyo) (1978) 2.70
Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. Diagn Microbiol Infect Dis (1998) 2.67
Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis (1994) 2.67
Delirium accelerates cognitive decline in Alzheimer disease. Neurology (2009) 2.67
In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. Antimicrob Agents Chemother (1997) 2.65
Antimicrobial resistance of pneumococci in children with acute lower respiratory tract infection in Pakistan. Lancet (1991) 2.63
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother (1997) 2.63